Is DIZZINESS a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed DIZZINESS.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 65 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported DIZZINESS to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and DIZZINESS. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause DIZZINESS, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes DIZZINESS. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if DIZZINESS ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing DIZZINESS: 65
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where DIZZINESS is a reported side effect: 1.9525%

FDA reports of any drug causing DIZZINESS : 132801
Average percentage for all medicated patients where DIZZINESS is reported as a complication: 0.8323%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with DIZZINESS:

ASPIRIN (11600 patients)
VIOXX (7378 patients)
LYRICA (6860 patients)
FOSAMAX (5996 patients)
FORTEO (5954 patients)
LIPITOR (5176 patients)
LISINOPRIL (4887 patients)
SYNTHROID (4476 patients)
SEROQUEL (4354 patients)
HEPARIN SODIUM INJECTION (3939 patients)
PAXIL (3927 patients)
NEXIUM (3724 patients)
ATENOLOL (3642 patients)
CYMBALTA (3597 patients)
DIGOXIN (3592 patients)
LASIX (3474 patients)
SIMVASTATIN (3462 patients)
BYETTA (3410 patients)
PLAVIX (3379 patients)
HUMIRA (3370 patients)
NEURONTIN (3252 patients)
PREDNISONE (3235 patients)
ENBREL (3099 patients)
COUMADIN (3094 patients)
CHANTIX (3093 patients)
XANAX (3083 patients)
HYDROCHLOROTHIAZIDE (3080 patients)
FUROSEMIDE (3079 patients)
NORVASC (2961 patients)
TYSABRI (2952 patients)
ZOLOFT (2880 patients)
OMEPRAZOLE (2836 patients)
DIOVAN (2690 patients)
TOPROL-XL (2659 patients)
METFORMIN HCL (2632 patients)
ZOCOR (2483 patients)
ZOMETA (2466 patients)
LEVOTHYROXINE SODIUM (2438 patients)
FOLIC ACID (2398 patients)
AMBIEN (2378 patients)
PRILOSEC (2373 patients)
CRESTOR (2338 patients)
ALBUTEROL (2309 patients)
CELEBREX (2296 patients)
VITAMIN D (2246 patients)
REMICADE (2244 patients)
AVONEX (2214 patients)
LEXAPRO (2189 patients)
METHOTREXATE (2180 patients)
PROTONIX (2174 patients)
IBUPROFEN (2089 patients)
PREVACID (2079 patients)
LANTUS (2049 patients)
CALCIUM (1959 patients)
GABAPENTIN (1926 patients)
LORAZEPAM (1915 patients)
COREG (1895 patients)
NIASPAN (1888 patients)
EFFEXOR XR (1866 patients)
METOPROLOL TARTRATE (1858 patients)
ACETAMINOPHEN (1845 patients)
ADVAIR DISKUS 100/50 (1837 patients)
WARFARIN SODIUM (1821 patients)
CLONAZEPAM (1782 patients)
VICODIN (1736 patients)
POTASSIUM CHLORIDE (1714 patients)
ALLOPURINOL (1636 patients)
LEVAQUIN (1611 patients)
ATIVAN (1604 patients)
EFFEXOR (1595 patients)
PREMARIN (1591 patients)
NAMENDA (1587 patients)
SANDOSTATIN LAR (1547 patients)
LAMICTAL (1533 patients)
WELLBUTRIN (1519 patients)
KLONOPIN (1515 patients)
AMLODIPINE (1514 patients)
FLOMAX (1503 patients)
AVELOX (1487 patients)
OXYCONTIN (1484 patients)
MULTI-VITAMIN (1465 patients)
DIAZEPAM (1453 patients)
PROZAC (1448 patients)
SINGULAIR (1440 patients)
PERCOCET (1426 patients)
PRISTIQ (1425 patients)
PRADAXA (1392 patients)
SPIRIVA (1390 patients)
DURAGESIC-100 (1342 patients)
METOPROLOL (1339 patients)
AREDIA (1332 patients)
INSULIN (1328 patients)
ALPRAZOLAM (1307 patients)
MULTI-VITAMINS (1298 patients)
NITROGLYCERIN (1284 patients)
GLUCOPHAGE (1271 patients)
AVANDIA (1257 patients)
VALIUM (1245 patients)
COZAAR (1231 patients)
ZETIA (1224 patients)
RIBAVIRIN (1219 patients)
ZYRTEC (1201 patients)
CELEXA (1195 patients)
ACTOS (1180 patients)
PREDNISONE TAB (1157 patients)
TRAMADOL HCL (1152 patients)
ZYPREXA (1121 patients)
DEXAMETHASONE (1117 patients)
ZANTAC (1114 patients)
FISH OIL (1113 patients)
ALLEGRA (1113 patients)
SPIRONOLACTONE (1112 patients)
GLIPIZIDE (1110 patients)
BENADRYL (1109 patients)
TOPAMAX (1096 patients)
TEGRETOL (1089 patients)
ACCUTANE (1088 patients)
GILENYA (1086 patients)
GLYBURIDE (1086 patients)
TRAZODONE HCL (1086 patients)
METFORMIN (1076 patients)
RISPERDAL (1076 patients)
PAROXETINE HCL (1070 patients)
PEGASYS (1053 patients)
VITAMIN B-12 (1042 patients)
OXYCODONE HCL (1028 patients)
LORTAB (1026 patients)
CITALOPRAM HYDROBROMIDE (1026 patients)
CARVEDILOL (1021 patients)
VALTREX (1021 patients)
VITAMIN E (1021 patients)
ZOFRAN (1019 patients)
MORPHINE (1019 patients)
REBIF (1018 patients)
ALTACE (999 patients)
LEVOXYL (995 patients)
TYLENOL (990 patients)
MIRENA (987 patients)
REVLIMID (974 patients)
TYLENOL (CAPLET) (965 patients)
FLEXERIL (962 patients)
HUMALOG (956 patients)
ASCORBIC ACID (955 patients)
PREDNISOLONE (953 patients)
AMITRIPTYLINE HCL (953 patients)
CLOZARIL (943 patients)
RAMIPRIL (929 patients)
ENALAPRIL MALEATE (927 patients)
CLONIDINE (926 patients)
RANITIDINE (904 patients)
AMOXICILLIN (896 patients)
BACLOFEN (895 patients)
YASMIN (863 patients)
AMARYL (853 patients)
DEPAKOTE (839 patients)
LOPRESSOR (838 patients)
FLONASE (836 patients)
ACTONEL (829 patients)
CLARITIN (821 patients)
METOPROLOL SUCCINATE (821 patients)
LANSOPRAZOLE (818 patients)
CALCIUM CARBONATE (813 patients)
ABILIFY (809 patients)
YAZ (808 patients)
ACIPHEX (798 patients)
VERAPAMIL (793 patients)
DECADRON (791 patients)
FENTANYL (789 patients)
STRATTERA (779 patients)
NAPROXEN (773 patients)
PEG-INTRON (764 patients)
EXJADE (761 patients)
TRICOR (761 patients)
ACETYLSALICYLIC ACID SRT (754 patients)
KEPPRA (752 patients)
BENICAR (747 patients)
BONIVA (746 patients)
DILANTIN (744 patients)
DIOVAN HCT (739 patients)
VYTORIN (736 patients)
ALEVE (736 patients)
TRILEPTAL (736 patients)
MECLIZINE (736 patients)
REGLAN (733 patients)
TRACLEER (731 patients)
CARDIZEM (730 patients)
NICODERM CQ (724 patients)
BETASERON (720 patients)
HEPARIN SODIUM (719 patients)
TEMAZEPAM (719 patients)
ULTRAM (716 patients)
ZELNORM (715 patients)
ALENDRONATE SODIUM (702 patients)
PRAVACHOL (700 patients)
VITAMINS (695 patients)
ALDACTONE (692 patients)
POTASSIUM (692 patients)
CIPROFLOXACIN (679 patients)
DILTIAZEM (678 patients)
IRON (675 patients)
MIRTAZAPINE (674 patients)
HYDROCODONE (674 patients)
COMPAZINE (673 patients)
PRAVASTATIN (670 patients)
SOLIRIS (669 patients)
PEPCID (657 patients)
MULTIVITAMIN (656 patients)
PROMETHAZINE (656 patients)
AMLODIPINE BESYLATE (656 patients)
ZITHROMAX (656 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about DIZZINESS and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.